

How many *mcr-1*-harbouring bacteria were spreading geographically?

Kwang Seung Park^{1#}, Jung Hun Lee^{1#}, Moonhee Park^{1,2}, Kwan Soo Ko³, Sang Hee Lee^{1*}

¹Department of Biological Sciences, National Leading Research Laboratory of Drug Resistance Proteomics, Myongji University, Myongjiro, Yongin, Gyeonggido, Republic of Korea

²Division of DNA Analysis, Seoul institute, National Forensic Service, Jiyangro, Yangcheongu, Seoul, Republic of Korea

³Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon, Republic of Korea

#These authors contributed equally to this work

Abstract

Colistin is widely used as an antibiotic of last resort for treating infections caused by multidrug-resistant gram-negative bacteria such as carbapenemase-producing *Enterobacteriaceae*. Recently, the emergence of plasmid-mediated (horizontally-transferable) colistin resistance (*mcr-1*) has become a great challenge to global public health. The *mcr-1* gene was detected in ESBL (Extended Spectrum β -Lactamase)-producing and/or carbapenemase-producing *Enterobacteriaceae*. Therefore, there is a huge risk of the emergence of pan-drug-resistant gram-negative bacteria. In this paper we discuss the epidemiological analyses of *mcr-1* positive *Enterobacteriaceae* and structural analyses of PmrC that was recently identified as a protein associated with colistin resistance.

Keywords: Plasmid-mediated colistin resistance, *Mcr-1*, Epidemiology, Dissemination, PmrC.

Accepted on September 14, 2016

Introduction

If antibiotic resistant pathogens remain unchecked, it is estimated that by 2050 the global mortality attributed to antibiotic-resistant bacterial infections will soar to 10 million, at a cost of over \$100 trillion (<http://amr-review.org/>). The spread of carbapenemase-producing *Enterobacteriaceae* is a significant threat to public health. For serious infections caused by carbapenemase-producing *Enterobacteriaceae*, the treatment options are restricted and invariably rely on tigecycline and colistin [1]. Therefore, the global increase in carbapenemase-producing *Enterobacteriaceae* has resulted in increased use of colistin with the inevitable risk of emerging resistance. Colistin resistance has involved chromosomal mutations but has never been reported via horizontal gene transfer. However, a plasmid-mediated (horizontally-transferable) colistin resistance (*mcr-1*) gene was recently reported in China [1] and subsequently detected in Asia (Vietnam, Laos, Thailand, Cambodia, Malaysia, Singapore, Taiwan and Japan), Europe (The Netherlands, Germany, Belgium, Switzerland, France, Denmark, United Kingdom, Spain, Italy, Sweden and Portugal), Africa (Algeria, Egypt, South Africa and Tunisia), and America (Canada, Argentina and Brazil) (Figure 1) [2-47]. We also found two *Escherichia coli* isolates harbouring *mcr-1* gene (GenBank accession no. KU886144 from a human being in Ecuador and GenBank accession no. KU743383 from a pig slurry in Estonia) in the

public NCBI database. To investigate how many *mcr-1* positive *Enterobacteriaceae* have been spreading globally, we analysed all these findings that were searched from the following databases PubMed, Medline, Embase, NCBI, and Google Scholar as of 4th May 2016. The analysis results showed the following important aspects: (i) the *mcr-1*-harboring bacteria had spread to most continents; (ii) four further studies are needed to fight against plasmid-mediated (horizontally-transferable) colistin resistance, particularly in pan-drug-resistant gram-negative bacteria.

Recent global dissemination of *mcr-1*-harbouring *Enterobacteriaceae*

As of 4th May 2016, 863 *mcr-1* positive *Enterobacteriaceae* (*Escherichia coli*, *Klebsiella pneumoniae*, *Salmonella enterica*, *Enterobacter aerogenes*, *Enterobacter cloacae*, human gut microorganisms and so on) were detected globally and *mcr-1*-harbouring bacteria have mainly spread in Asia (n=550) and Europe (n=224) (Figure 1) [1-42]. Because in most studies *mcr-1* carriers have been identified from random sample collections, the reliable prevalence of *mcr-1* positive isolates is not known. In America, only 29 isolates (or 60 in Africa) were detected in animal and/or human being [11,19,21,43-47].

550 (63.7%) of 863 *mcr-1* positive *Enterobacteriaceae* were detected in Asia [1,9,13,15-17,20,21,27-32,35-41] [26.0% in

Europe [2-8,10,12,14,17,22-26,33,34,42], 7.0% in Africa [11,21,43,44,46] and 3.3% in America [19,45,47]. *mcr-1* positive isolates were distributed to adjacent countries in Asia (or Europe), suggesting the easy spread by a potential travel dissemination pathway as well as a possible dissemination pathway through international trade of foods.

Of note, the spread between Asia and Europe might be allowed by a potential travel dissemination pathway (from China, Vietnam, Laos, Thailand and Cambodia to Netherlands), a potential dissemination pathway by international trade of food

(fresh vegetables; from Thailand and Vietnam to Switzerland) or a potential dissemination pathway speculated by the sequence comparison of the isolated plasmids (from China to Portugal) (Figure 1) [4,33,42]. The *mcr-1* dissemination between Europe and North Africa might be allowed by a potential travel dissemination pathway (from Tunisia to Netherlands) or a potential dissemination pathway through international trade of foods (chickens, from France to Tunisia) (Figure 1) [4,11].




Figure 1. Epidemiological features of *mcr-1*-harboring *Enterobacteriaceae* (as of 4th May 2016). The size of circle is not proportional to the amount of *mcr-1* positive isolates. The deeper color means the more amounts of *mcr-1* positive isolates.

Scope for further studies

First, *mcr-1* positive isolates from human beings were detected after the dissemination of New Delhi Metallo- β -lactamase-1 (NDM-1) positive *Enterobacteriaceae* that were susceptible to tigecycline and colistin. The limitation of colistin use in treatment of infection via ESBL-producing/*mcr-1*-harboring gram-negative bacteria [4,7,10-12,14,19,29,30,35,38] or carbapenemase-producing/*mcr-1*-harboring Gram-negative bacteria [9,24,35] may increase tigecycline use and then the possibility of emergence of tigecycline resistance mechanisms other than an efflux pump. To prevent the emergence of a pan-drug resistance in gram-negative bacteria, the continued monitoring of colistin and/or tigecycline resistance and their underlining mechanisms in human, animal, food and environmental sources have to be required.

Second, 162 (18.8%) of 863 *mcr-1* positive *Enterobacteriaceae* were investigated about plasmids associated with *mcr-1* gene

and harboured a low variety of plasmids (IncI2, IncHI1, IncHI2, IncP, IncFI and IncX4) [4,9-13,18,19,23,24,30,32,33,35,38,41]. To clarify the diversity of the plasmid backbones spreading *mcr-1* gene within the remaining 701 isolates or isolates detected in the future, additional studies about the plasmids (or the mobile elements) are needed. Like chromosomal localization of the commonly plasmid-borne *qnrB* (plasmid-mediated quinolone resistance) genes, the chromosomal location of *mcr-1* gene associated with a mobile element such as *ISApI1* may be observed in the near future. In addition to the plasmid itself, the mobile element alone can represent the transfer mechanism of *mcr-1* into *Enterobacteriaceae*.

Finally, *mcr-1* gene was not detected in 803 (48.2%) of 1,666 colistin resistant *Enterobacteriaceae* [1-44,46,47], suggesting that they might potentially harbour other colistin-resistant mechanism (probably, new groups of MCR) or even novel *mcr-1* alleles. The *pmrC* gene was recently identified as a gene

associated with colistin resistance by our group [48]. Homology modelling of *MCR-1* and PmrC were performed by an automated homology modelling approach using LptA (PDB ID 4KAY) and EptC (PDB ID 4TN0) as templates in Swiss-Model (<http://swissmodel.expasy.org/>) program. Although PmrC showed 29% amino acid sequence identity to the *MCR-1* sequence, the Root Mean Square Deviation (RMSD) of the C α trace between PmrC and *MCR-1* models was 1.0 Å, supporting that PmrC structure was quite similar to *MCR-1* structure as described in the supplementary appendix (Figure S1, available as supplementary material). Structure-based alignment of PmrC, *MCR-1*, LptA and EptC revealed that key residues identified as to be important to the catalytic activity of LptA and EptC are conserved in PmrC and *MCR-1* (Figure S2, available as Supplementary Material). Taken together, the PmrC predicted structure is consistent with a lipid A phosphoethanolamine transferase, which was functionally confirmed by lipid A analysis as previously described [48]. Therefore, the PmrC may probably be another group of MCR. However, further studies are needed to confirm the hypothesis that PmrC may be a new group of MCR in addition to *MCR-1* group and continuously monitor another group of MCR.

Supplementary Data

Figures S1 and S2 are available as Supplementary Materials.

Conflict of Interests

The authors declare that they have no competing interests.

Acknowledgments

This work was supported by research grants from the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (No. 2011-0027928 and No. 2016R1C1B2010308) and Marine Biotechnology Program (20150581, Development of Technology for Biohydrogen Production using Hyperthermophilic Archaea) Funded by Ministry of Oceans and Fisheries in Republic of Korea.

References

1. Liu YY, Wang Y, Walsh TR, Yi LX, Zhang R, Spencer J, Doi Y, Tian G, Dong B, Huang X, Yu LF, Gu D, Ren H, Chen X, Lv L, He D, Zhou H, Liang Z, Liu JH, Shen J. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: A microbiological and molecular biological study. *Lancet Infect Dis* 2016; 16: 161-168.
2. Hasman H, Hammerum AM, Hansen F, Hendriksen RS, Olesen B, Agersø Y, Zankari E, Leekitcharoenphon P, Stegger M, Kaas RS, Cavaco LM, Hansen DS, Aarestrup FM, Skov RL. Detection of *mcr-1* encoding plasmid-mediated colistin-resistant *Escherichia coli* isolates from human bloodstream infection and imported chicken meat. *Euro Surveill* 2015; 20: 30085.
3. Anjum MF, Duggett NA, AbuOun M, Randall L, Nunez-Garcia J, Ellis RJ, Rogers J, Horton R, Brena C, Williamson S, Martelli F, Davies R, Teale C. Colistin resistance in *Salmonella* and *Escherichia coli* isolates from a pig farm in Great Britain. *J Antimicrob Chemother* 2016; 71: 2306-2313.
4. Arcilla MS, van Hattem JM, Matamoros S, Melles DC, Penders J. Dissemination of the *mcr-1* colistin resistance gene. *Lancet Infect Dis* 2016; 16: 147-149.
5. Bakterie resistent mot sista behandlingsalternativet funnen. Bacteria resistant to the last treatment option found. Press Stockholm Folkhalsomyndigheten 2016; 10.
6. Battisti A. Antibiotic resistance-Italy: colistin, MCR-1, *E. coli*. *Pro Med* 2016.
7. Cannatelli A, Giani T, Antonelli A, Principe L, Luzzaro F. First detection of the *mcr-1* colistin resistance gene in *Escherichia coli* in Italy. *Antimicrob Agents Chemother* 2016; 60: 3257-3258.
8. Doumith M, Godbole G, Ashton P, Larkin L, Dallman T, Day M, Day M, Muller-Pebody B, Ellington MJ, de Pinna E, Johnson AP, Hopkins KL, Woodford N. Detection of the plasmid-mediated *mcr-1* gene conferring colistin resistance in human and food isolates of *Salmonella enterica* and *Escherichia coli* in England and Wales. *J Antimicrob Chemother* 2016; 71: 2300-2305.
9. Du H, Chen L, Tang YW, Kreiswirth BN. Emergence of the *mcr-1* colistin resistance gene in carbapenem-resistant Enterobacteriaceae. *Lancet Infect Dis* 2016; 16: 287-288.
10. Falgenhauer L, Waezsada SE, Yao Y, Imirzalioglu C, Käsböhrer A, Roesler U, Michael GB, Schwarz S, Werner G, Kreienbrock L, Chakraborty T. Colistin resistance gene *mcr-1* in extended-spectrum β -lactamase-producing and carbapenemase-producing Gram-negative bacteria in Germany. *Lancet Infect Dis* 2016; 16: 282-283.
11. Grami R, Mansour W, Mehri W, Bouallegue O, Boujaâfar N. Impact of food animal trade on the spread of *mcr-1*-mediated colistin resistance, Tunisia. *Euro Surveill* 2016; 21: 30144.
12. Haenni M, Poirel L, Kieffer N, Chatre P, Saras E. Co-occurrence of extended spectrum β lactamase and MCR-1 encoding genes on plasmids. *Lancet Infect Dis* 2016; 16: 281-282.
13. Hu Y, Liu F, Lin IY, Gao GF, Zhu B. Dissemination of the *mcr-1* colistin resistance gene. *Lancet Infect Dis* 2016; 16: 146-147.
14. Kluytmans-van den Bergh MF, Huizinga P, Bonten MJ, Bos M, De Bruyne K. Presence of *mcr-1*-positive Enterobacteriaceae in retail chicken meat but not in humans in the Netherlands since 2009. *Euro Surveill* 2016; 21: 30149.
15. Kuo SC, Huang WC, Shiau YR, Cheng MF, Lauderdale TL. Colistin resistance gene *mcr-1* in *Escherichia coli* isolates from humans and retail meats, Taiwan. *J Antimicrob Chemother* 2016; 71: 2327-2329.
16. Li A, Yang Y, Miao M, Chavda KD, Mediavilla JR, Xie X, Feng P, Tang YW, Kreiswirth BN, Chen L, Du H. Complete sequences of *mcr-1*-harboring plasmids from extended-spectrum- β -lactamase-and carbapenemase-producing

- Enterobacteriaceae. *Antimicrob Agents Chemother* 2016; 60: 4351-4354.
17. Malhotra-Kumar S, Xavier BB, Das AJ, Lammens C, Butaye P. Colistin resistance gene *mcr-1* harboured on a multidrug resistant plasmid. *Lancet Infect Dis* 2016; 16: 283-284.
 18. Malhotra-Kumar S, Xavier BB, Das AJ, Lammens C, Hoang HT. Colistin-resistant *Escherichia coli* harbouring *mcr-1* isolated from food animals in Hanoi, Vietnam. *Lancet Infect Dis* 2016; 16: 286-287.
 19. Mulvey MR, Mataseje LF, Robertson J, Nash JH, Boerlin P. Dissemination of the *mcr-1* colistin resistance gene. *Lancet Infect Dis* 2016; 16: 289-290.
 20. Nguyen NT, Nguyen HM, Nguyen CV, Nguyen TV, Nguyen MT, Thai HQ, Ho MH, Thwaites G, Ngo HT, Baker S, Carrique-Mas J. Use of colistin and other critical antimicrobials on pig and chicken farms in southern Vietnam and their association with resistance in commensal *Escherichia coli* bacteria. *Appl Environ Microbiol* 2016; 82: 3727-3735.
 21. Olaitan AO, Chabou S, Okdah L, Morand S, Rolain JM. Dissemination of the *mcr-1* colistin resistance gene. *Lancet Infect Dis* 2016; 16: 147.
 22. Perrin-Guyomard A, Bruneau M, Houee P, Deleurme K, Legrandois P. Prevalence of *mcr-1* in commensal *Escherichia coli* from French livestock, 2007 to 2014. *Euro Surveill* 2016; 21: 30135.
 23. Petrillo M, Angers-Loustau A, Kreysa J. Possible genetic events producing colistin resistance gene *mcr-1*. *Lancet Infect Dis* 2016; 16: 280.
 24. Poirel L, Kieffer N, Liassine N, Thanh D, Nordmann P. Plasmid-mediated carbapenem and colistin resistance in a clinical isolate of *Escherichia coli*. *Lancet Infect Dis* 2016; 16: 281.
 25. Prim N, Rivera A, Rodriguez-Navarro J, Espanol M, Turbau M. Detection of *mcr-1* colistin resistance gene in polyclonal *Escherichia coli* isolates in Barcelona, Spain, 2012 to 2015. *Euro Surveill* 2016; 21: 30183.
 26. Quesada A, Ugarte-Ruiz M, Rocio Iglesias M, Concepcion Porrero M, Martinez R, Florez-Cuadrado D, Campos MJ, Garcia M, Piriz S, Saez JL, Dominguez L. Detection of plasmid mediated colistin resistance (MCR-1) in *Escherichia coli* and *Salmonella enterica* isolated from poultry and swine in Spain. *Res Vet Sci* 2016; 105: 134-135.
 27. Ruppe E, Le Chatelier E, Pons N, Andreumont A, Ehrlich SD. Dissemination of the *mcr-1* colistin resistance gene. *Lancet Infect Dis* 2016; 16: 290-291.
 28. Shen Z, Wang Y, Shen Y, Shen J, Wu C. Early emergence of *mcr-1* in *Escherichia coli* from food-producing animals. *Lancet Infect Dis* 2016; 16: 293.
 29. Stoesser N, Mathers AJ, Moore CE, Day NP, Crook DW. Colistin resistance gene *mcr-1* and pHNSHP45 plasmid in human isolates of *Escherichia coli* and *Klebsiella pneumoniae*. *Lancet Infect Dis* 2016; 16: 285-286.
 30. Suzuki S, Ohnishi M, Kawanishi M, Akiba M, Kuroda M. Investigation of a plasmid genome database for colistin-resistance gene *mcr-1*. *Lancet Infect Dis* 2016; 16: 284-285.
 31. Teo JQM, Cai Y, Lim TP, Tan TT, Kwa ALH. Carbapenem resistance in Gram-negative bacteria: the not-so-little problem in the little red dot. *Microorganisms* 2016; 4: 13.
 32. Pham TD, Thanh TH, Nguyen TNT, Chung TH, Wick RR, Thwaites GE, Baker S, Holt KE. Inducible colistin resistance via a disrupted plasmid-borne *mcr-1* gene in a 2008 Vietnamese *Shigella sonnei* isolate. *J Antimicrob Chemother* 2016; 71: 2314-2317.
 33. Tse H, Yuen KY. Dissemination of the *mcr-1* colistin resistance gene. *Lancet Infect Dis* 2016; 16: 145-146.
 34. Webb HE, Granier SA, Marault M, Millemann Y, den Bakker HC. Dissemination of the *mcr-1* colistin resistance gene. *Lancet Infect Dis* 2016; 16: 144-145.
 35. Yao X, Doi Y, Zeng L, Lv L, Liu JH. Carbapenem-resistant and colistin-resistant *Escherichia coli* co-producing NDM-9 and MCR-1. *Lancet Infect Dis* 2016; 16: 288-289.
 36. Ye H, Li Y, Li Z, Gao R, Zhang H. Diversified *mcr-1*-harbouring plasmid reservoirs confer resistance to colistin in human gut microbiota. *MBio* 2016; 7: e00177.
 37. Yu CY, Ang GY, Chin PS, Ngeow YF, Yin WF. Emergence of *mcr-1*-mediated colistin resistance in *Escherichia coli* in Malaysia. *Int J Antimicrob Agents* 2016; 47: 504-505.
 38. Zeng KJ, Doi Y, Patil S, Huang X, Tian GB. Emergence of the plasmid-mediated *mcr-1* gene in colistin-resistant *Enterobacter aerogenes* and *Enterobacter cloacae*. *Antimicrob Agents Chemother* 2016; 60: 3862-3863.
 39. Zhang R, Huang Y, Chan EW, Zhou H, Chen S. Dissemination of the *mcr-1* colistin resistance gene. *Lancet Infect Dis* 2016; 16: 291-292.
 40. Zhang XF, Doi Y, Huang X, Li HY, Zhong LL, Zeng KJ, Zhang YF, Patil S, Tian GB. Possible transmission of *mcr-1*-harboring *Escherichia coli* between companion animals and human. *Emerg Infect Dis* 2016; 22: 1679-1681.
 41. Zhi C, Lv L, Yu LF, Doi Y, Liu JH. Dissemination of the *mcr-1* colistin resistance gene. *Lancet Infect Dis* 2016; 16: 292-293.
 42. Zurfluh K, Poirel L, Nordmann P, Nuesch-Inderbinen M, Hachler H, Stephan R. Occurrence of the plasmid-borne *mcr-1* colistin resistance gene in ESBL-producing *Enterobacteriaceae* in river water and imported vegetable samples in Switzerland. *Antimicrob Agents Chemother* 2016; 60: 2594-2595.
 43. Coetzee J, Corcoran C, Prentice E, Moodley M, Mendelson M, Poirel L, Nordmann P, Brink AJ. Emergence of plasmid-mediated colistin resistance (MCR-1) among *Escherichia coli* isolated from South African patients. *S Afr Med J* 2016; 106: 449-450.
 44. Elnahriry SS, Khalifa HO, Soliman AM, Ahmed AM, Moustafa AH, Shimamoto T, Shimamoto T. Emergence of plasmid-mediated colistin resistance gene, *mcr-1*, in a

How many mcr-1-harboursing bacteria were spreading geographically?

- clinical *Escherichia coli* isolate from Egypt. *Antimicrob Agents Chemother* 2016; 60: 32449-3250.
45. Fernandes MR, Moura Q, Sartori L, Silva KC, Cunha MP, Esposito F, Lopes R, Otutumi LK, Gonçalves DD, Dropa M, Matte MH, Monte DF, Landgraf M, Francisco GR, Bueno MF, de Oliveira Garcia D, Knobl T, Moreno AM, Lincopan N. Silent dissemination of colistin-resistant *Escherichia coli* in South America could contribute to the global spread of the *mcr-1* gene. *Euro Surveill* 2016; 21: 30214.
46. Khalifa HO, Ahmed AM, Oreiby AF, Eid AM, Shimamoto T. Characterisation of the plasmid-mediated colistin resistance gene *mcr-1* in *Escherichia coli* isolated from animals in Egypt. *Int J Antimicrob Agents* 2016; 47: 413-414.
47. Rapoport M, Faccone D, Pasteran F, Ceriana P, Albornoz E, Petroni A, Corso A. *Mcr-1*-mediated colistin resistance in human infections caused by *Escherichia coli*: First description in Latin America. *Antimicrob Agents Chemother* 2016; 60: 4412-4413.
48. Park YK, Lee JY, Ko KS. Transcriptomic analysis of colistin susceptible and colistin resistant isolates identifies genes associated with colistin resistance in *Acinetobacter baumannii*. *Clin Microbiol Infect* 2015; 21: e1-7.

***Correspondence to**

Sang Hee Lee
Department of Biological Sciences
Myongji University
Republic of Korea